Pharmaceutical Business Review
Anonymous User | Login

Clarient Launches New Gene Mutation Test

Published: 16-Jun-2009

EGFR activates pathway that leads to cell proliferation

Clarient has announced the launch of a new gene mutation test, that can help physicians select the proper therapy for patients with non-small cell lung cancer (NSCLC). The test, called epidermal growth factor receptor (EGFR) mutation, has been validated as a laboratory-developed test.

EGFR activates an important pathway that leads to cell proliferation, lack of differentiation, and enhanced cell survival and gene transcription.

Ron Andrews, CEO of Clarient, said: Our new EGFR mutation test can be used as a predictive molecular biomarker to explain why a subset of patients with non-small cell lung cancer may respond to EGFR tyrosine kinase inhibitor (TKI) therapies.

This information can help pathologists and oncologists improve the overall management of this difficult disease, he added.

Mail sent successfully

Tell your friend about this article


Please enter a valid email address

Please enter your name

Please enter the mail body


Your Name: *
Your Email: *
Friend's Email: *
Email Body: *
 

Suppliers To This Sector

Browse A-Z

# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

AR2i

Liquid Handling, Laboratory Material and Technology, Aparatus, Automation and Glassware ...

Lonza Custom Manufacturing

Bioresearch Products, Development Services and Manufacturing for Functional and Active Ingredients ...

NovAliX

Small Molecule Drug Discovery ...

Umetrics

Multivariate Data Analysis Software ...

ELPRO

High Quality Temperature and Humidity Dataloggers ...

Kuecept

Concept Formulation Design ...

White Papers

Browse A-Z

# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Your IP at Risk in Collaborations!

Free white paper: Ten steps to protect your R&D investment within partnerships. ...

Why, When and How to Conduct 14C Human Studies

Several risk-based strategies to assess metabolites exist. Whatever the strategy chosen, t ...

Why CAPA Still Matters

This free white paper explores the needs and effectiveness of correct CAPA control, how to ...

Water Treatment

From the control room to the downstream processing area and with an eye on utilities servi ...

Using the Mean Kinetic Temperature (MKT) As a Parameter to Determine Whether Perishable Goods Have Been Transported and Stored Correctly

Tecnosoft systems use MKT calculation to control the acquired values and report the user w ...

USB HotStart-IT for Real Time PCR

USBĀ® Products from Affymetrix have a long-standing reputation in the life science marketpl ...

Related Companies

Laboratory Corporation of America Holdings

Laboratory Corporation of America Holdings (LabCorp) is engaged in providing a wide ran ...

Quest Diagnostics Incorporated

Quest Diagnostics Incorporated (Quest), a medical diagnostics company, is a provider of ...

Clarient, Inc.

Clarient, Inc. (Clarient) is a cancer diagnostic company engaged in providing cellular ...

Suppliers Product News

Novalyst Discovery and AliX Agree to Merge NovAliX Launch

Integrating structural biology and medicinal chemistry.

AliX and SOSHO to Sign Agreement for Protein Structure Determination of Intractable Targets

Breakthrough crystallisation technology for protein structure determination.

Kuecept and The School of Pharmacy Agree Key Drug Delivery Licensing

Kuecept Ltd and The School of Pharmacy, University of London agree key drug delivery licensing deals to facilitate the development of low solubility, poorly bioavailable compounds.

Synectix Pharmaceutical Solutions Now Called Kuecept

Synectix Pharmaceutical Solutions Ltd, the speciality drug development company, announced today that effective immediately, the company has changed its name to Kuecept Ltd.

Free Newsletter Sign-up

Sign up, and we will send you a free Pharmaceutical report on “ Combination Products – Evolution of the Medical Equipment Industry” from GlobalData worth $750

Please enter a valid email address